AstraZeneca is a global, science-led biopharmaceutical company that discovers, develops, and commercializes prescription medicines. Through its venture arm and partnerships — including the AstraZeneca-CICC Healthcare Investment Fund — it invests in innovative therapeutics, medical technologies, and healthcare companies.
50% of their portfolio is in Biotech & Life Sciences. Deal activity increased 600% year-over-year (7 deals in the last 12 months). Average disclosed round size is $91.9M (across 21 rounds with reported amounts).
Portfolio
18
Fund Size
$1B
Top Stage
Series B
Last 12 Mo
7
Team
Anna Manz
Non-Executive Director
Aradhana Sarin
Executive Director and CFO
Diana Layfield
Non-Executive Director
Karen Knudsen
Non-Executive Director
Marcus Wallenberg
Non-Executive Director
Pascal Soriot
Executive Director and CEO
Philip Broadley
Senior independent Non-Executive Director
Sheri McCoy
Non-Executive Director
Tony Mok
Non-Executive Director
Wan Ling Martello
Non-Executive Director
Portfolio Breakdown
Stage Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Yoltech Therapeutics | Series C | $70M | May 2026 |
| YYolTech | Series C | $70M | May 2026 |
| SSyneron Bio | Series B | $150M | Mar 2026 |
 Entasis | Series B | $50M | Jan 2026 |
| SSyneron Bio | Series A | — | Dec 2025 |
 Cassidy Bio | Seed | $8M | Nov 2025 |
| Yoltech Therapeutics | Series B | $45M | Sep 2025 |
| YYolTech | Series B | $45M | Sep 2025 |
 Promise Bio | Seed | $8.3M | Dec 2024 |
| HHuma Therapeutics | Series D | — | Jul 2024 |
 Asher Bio | Series C | $55M | Jan 2024 |
| SSixpeaks Bio | Series A | $30M | Jan 2024 |
| AAsher Biotherapeutics | Series C | $55M | Jan 2024 |
| HHuma Therapeutics | Series D | $80M | Jan 2024 |
| QQuris AI | Seed | $37M | Jan 2022 |
 ADC Therapeutics | Series E | $76M | Jun 2019 |
| BBIODISCOVERY 5 | Unknown | $60M | Apr 2018 |
| Entasis | Series B | $50M | Mar 2016 |
 Acerta Pharma | Series B | $375M | Jan 2015 |
| MModerna Therapeutics | Unknown | $450M | Jan 2015 |
 PhaseBio Pharmaceuticals | Series C | $40M | — |
 Sortera Bio | Pre-Seed | — | — |
| PhaseBio Pharmaceuticals | Series D | $168M | — |
| CCassidy | Seed | $8M | — |
Top Co-Investors
Last updated: 7 October 2026